The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors

Haznedaroğlu, İbrahim C.

doi:10.4999/uhod.11011

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These and other innovative treatments have increased patients' life expectancy. 1,3 Cost-effectiveness analysis (CEA) is a technique to assess the benefit of interventions relative to their costs. Cost-utility analysis (CUA) is a type of CEA that measures health benefits in quality-adjusted lifeyears (QALYs).…”

Section: Introductionmentioning

confidence: 99%

Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses

Saret

Winn

Shah

et al. 2015

Blood

View full text Add to dashboard Cite

We analyzed cost-effectiveness studies related to hematologic malignancies from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), focusing on studies of innovative therapies. Studies that met inclusion criteria were categorized by 4 cancer types (chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma) and 9 treatment agents (interferon-α, alemtuzumab, bendamustine, bortezomib, dasatinib, imatinib, lenalidomide, rituximab alone or in combination, and thalidomide). We examined study characteristics and stratified cost-effectiveness ratios by type of cancer, treatment, funder, and year of study publication. Twenty-nine studies published in the years 1996-2012 (including 44 cost-effectiveness ratios) met inclusion criteria, 22 (76%) of which were industry funded. Most ratios fell below $50 000 per quality-adjusted life-years (QALY) (73%) and $100 000/QALY (86%). Industry-funded studies (n = 22) reported a lower median ratio ($26 000/QALY) than others (n = 7; $33 000/QALY), although the difference was not statistically significant. Published data suggest that innovative treatments for hematologic malignancies may provide reasonable value for money.

show abstract

Section: Introductionmentioning

confidence: 99%

Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses

Saret

Winn

Shah

et al. 2015

Blood

View full text Add to dashboard Cite

show abstract

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation

Bektas

Eliaçık

et al. 2011

Case Reports in Hematology

View full text Add to dashboard Cite

The current treatment of chronic phase chronic myeloid leukemia (CML) consists of oral tyrosine kinase inhibitors (TKIs). However, high-risk CML may present with an aggressive course which may result in blastic crisis or a “difficult-to-manage” state with available treatments. The aim of this paper is to report a patient with complicated CML resistant to treatment and progressed despite the administration of bosutinib, imatinib mesylate, nilotinib, dasatinib, interferon alpha 2a, cytotoxic chemotherapy, and allogeneic hematopoietic stem cell transplantation. The striking point of this case story is that no Abl kinase domain mutation against TKIs has been detected during this very complicated disease course of CML. Meanwhile, challenging cases will always be present despite the hope and progress in CML in the TKI era.

show abstract

The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors

Cited by 2 publications

References 11 publications

Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses

Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation

Contact Info

Product

Resources

About